Abstract:Background: Anxiety symptoms usually worsen depression and functional impairment. The present study was aimed to evaluate the impact of escitalopram on social function and quality of life in major depressive disorder (MDD) patients with anxiety symptoms. Patients and methods: Adult MDD patients with functional impairment (Sheehan Disability Scale [SDS] score >= 9) and anxiety symptoms (Hamilton Anxiety Rating Scale [HAM-A] score >= 14) received escitalopram (10-20 mg/day) for 8 weeks. Symptom status was assessed by SDS, Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form, Montgomery-Asberg Depression Rating Scale (MADRS), HAM-A, and Quick Inventory of Depressive Symptomatology Self Report scales. Safety was evaluated by treatment-emergent adverse events (TEAEs). Results: Overall, 208 (79.7%) of 261 enrolled patients completed the 8-week treatment. Mean (SD) SDS and Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form total scores were 17.4 (5.87) and 39.3 (14.43) at baseline, which improved to 7.6 (6.71) and 61.6 (15.80), respectively, at week 8. Totally, 59.2% of patients achieved functional remission (SDS <= 6) and 61.7% of patients achieved depression remission (MADRS <= 10) at week 8; 48.1% of patients achieved both functional and depression remission (SDS <= 6 and MADRS <= 10). The change in SDS total score was positively correlated with the change in MADRS and HAM-A total scores at each visit. Patient's baseline SDS score was related with depression score (regression coeflicient=0.40582, y=0.0005); remission of SDS was statistically related to a reduction of week 2 and week 6 HAM-A score (p<0.0001) and reduction of MADRS score (p<0.0001). Overall, 25.7% of patients reported r 1 TEAEs. Most frequently reported TEAEs were nausea (5.8%), diarrhea (2.3%), and dizziness (2.7%). Most TEAEs were mild to moderate in severity. Four patients reported serious TEAEs, two patients reported suicide attempts, and one patient completed suicide. Conclusion: Escitalopram (10-20 mg/day) treatment was efficacious in reducing depression, improving social function, and quality of life in MDD patients with anxiety symptoms. No new safety signals were identified.

Efficacy and safety of ethy1 loflazepate(34 patients) vs diazepam(32 patients) in treatment of anxiety disorders

Efficacy and Safety of Ethyl Loflazepate(21 Patients) Vs Diazepam(22 Patients) in Treatment of Anxiety Disorders

Comparison of ethyl loflazepate (79 patients) with diazepam (75 patients) in treatment of anxiety disorders:a randomized,multicenter,double-blind study

Efficacy and safety of olanzapine combined with fluoxetine in treatment of depression

Randomized,multicenter,double blind comparative trial of reboxetine in the treatment of depression with or without anxiety

A controlled trial of olanzapine and fluoxetine in treatment of negative symptoms of schizophrenia

Venlafaxine vs clomipramine in treating major depression associated with anxiety

A comparative study of treatment of depression:Mirtazapine vs.fluoxepine

A comparison study of sertraline,venlafxin and alprazolam in treatment of generalized anxiety disorder

A Multicenter, Randomized, and Double-Blind Controlled Clinical Trial of Lorazepam Injection Vs Diazepam Injection in Treatment of Anxiety State

Studies on the Bioequivalence of Lorazepam Tablet in Healthy Volunteers

A Clinical Study of Venlafaxine in the Treatment of Anxiety in Elderly Hypertensive Patients with Anxiety

Escitalopram and sertraline in treatment of depression with anxiety

A study on efficacy and safety of fluoxetine combined with olanzapine in the treatment of major depression

Safety and effectiveness of escitalopram in an 8-week open study in Chinese patients with depression and anxiety.

Effect of flupentixol/melitracen combined with lactulose on treatment of constipation in the elderly with anxiety

Effect and reliability of zaleplon on treatment of insomnia:a randomized,double-blind,controll study

A clinical study of the effects of amlodipine combined with flupentixol/melitracen and psychotherapy on es-sential hypertension in senile patients with mixed anxiety-depressive disorder

Randomized Double-Blind Control Study of Olanzapine Augmented with Fluoxetine for Schizophrenia with Depression Symptom

Clinical effects of venlafaxine in treatment of depressive disorder associated with anxiety and its impact factors

Clinical effect of reboxetine in the treatment of anxiety in depressive patients